Novo-Nordisk AS (ADRs)
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
30.93%
Market Cap
-
P/E Ratio
14.59
Dividend Yield
2.53 %
Earnings per Share
3.09 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 41.78 G | 0 Units |
| PRICE DETERMINATION TIME | 06/24/2026 / 09:55:58 PM | |
| DAILY VOLUME (UNITS) | 609 | |
| DAILY HIGH / LOW | 41.86 | 41.04 |
| PREV. DAY'S PRICE | 41.58 | (06/23) |
| CHANGE DAY BEFORE | +0.20 | 0.48 % |
| 52 WEEK HIGH / LOW | 62.6 (07/28) | 30.5 (03/30) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 2.85 | 2.88 | 3.09 | 3.04 | 2.51 |
| DIVIDENDS PER SHARE | 1.54 | 1.59 | 1.14 | 1.09 | 0.90 |
| DIVIDEND YIELD IN % | - | - | 2.53 % | 1.37 % | 0.94 % |
| DIVIDEND GROWTH IN % | - | - | 4.31 % | 21.01 % | 51.43 % |
| PRICE - EARNINGS RATIO | 13.20 | 13.08 | 14.59 | 26.16 | 38.19 |
| PRICE - BOOK RATIO | - | - | 7.41 | 19.17 | 29.21 |
| PRICE - SALES RATIO | - | - | 4.84 | 9.12 | 13.80 |
| PRICE - CASH FLOW RATIO | - | - | 12.56 | 21.88 | 29.43 |
Master Data
| WKN | 866931 |
| ISIN | US6701002056 |
| SYMBOL | NOVA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Novo Nordisk ADR |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 10.70 % | 7.39 % | 30.96 % | -5.82 % | -30.93 % | -43.43 % | 20.52 % | -5.71 % |
| HIGH | 41.62 | 41.62 | 41.62 | 54.60 | 62.60 | 139.50 | 139.50 | 54.60 |
| LOW | 37.28 | 35.58 | 30.50 | 30.50 | 30.50 | 30.50 | 30.50 | 30.50 |
Dividend
per share
Company profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Structured products for Novo-Nordisk AS (ADRs)
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.